Ozempic (Semaglutide)

O que é Ozempic?

Ozempic (semaglutide) is a once-weekly injectable receita médica medicamento that belongs to the GLP-1 receptor agonist class. It is approved by the Agência Europeia de Medicamentos (EMA) for the tratamento of type 2 diabetes in adults and is also used off-label by médicos for weight management in eligible pacientes.

Como funciona Ozempic work?

Ozempic works by mimicking the action of glucagon-like peptide-1 (GLP-1), a naturally occurring hormone released by the gut after eating. When semaglutide binds to GLP-1 receptors throughout the body, it triggers several clinically significant responses:

• Appetite suppression: Signals in the brain’s hypothalamus reduce hunger and increase feelings of fullness (satiety), leading to reduced caloric intake.
• Slowed gastric emptying: Food moves more slowly from the stomach to the small intestine, prolonging the sensation of fullness after meals.
• Blood glucose regulation: Semaglutide stimulates insulin release from the pancreas in response to food and suppresses the release of glucagon, a hormone that raises blood sugar levels.
• Cardiovascular effects: Clinical data published by the EMA indicates that semaglutide reduces the risk of major adverse cardiovascular events in pacientes with type 2 diabetes and established cardiovascular disease.

Because the GLP-1 receptors targeted by semaglutide are distributed across multiple organ systems — including the brain, gut, heart, and pancreas — Ozempic’s effects extend beyond blood sugar control to include meaningful body weight reduction.

Para quem é Ozempic for?

Ozempic is indicated for adults with type 2 diabetes mellitus when diet and exercise alone are insufficient to achieve adequate glycaemic control. In clinical practice, independent médicos may also consider prescribing semaglutide off-label for weight management in adults who meet specific eligibility criteria, typically including:

• A body mass index (BMI) of 30 or above, or
• A BMI of 27 or above with at least one weight-related comorbidity such as hypertension, dyslipidaemia, or obstructive sleep apnoea

Ozempic is not appropriate for everyone. It is not recommended for people with a personal or family history of medullary thyroid carcinoma (MTC), people with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or those who are pregnant or planning to become pregnant. A full medical assessment by a qualified médico is required before any receita médica can be issued.

Dosagem

Ozempic is administered once weekly by subcutaneous injeção (under the skin of the abdomen, thigh, or upper arm). The standard titration schedule, as per EMA-approved prescribing guidance, is:

Phase	Dose	Duration
Starting dose	0.25 mg once weekly	4 weeks
Maintenance step 1	0.5 mg once weekly	At least 4 weeks
Maintenance step 2 (if needed)	1 mg once weekly	Ongoing or as directed
Maximum dose	2 mg once weekly	As clinically indicated

The starting dose of 0.25 mg is used to minimise gastrointestinal efeito secundários during the initial weeks of tratamento. Dose escalation should only occur under a médico’s supervision. Patients should not adjust their dose without consulting their prescribing médico.

Ozempic is available as a pre-filled injeção pen. Injections can be given at any time of day, with or without food.

Efeitos secundários

As with all medicamentos, Ozempic may cause efeito secundários. Not all pacientes experience them, and many resolve as the body adapts to the medication.

Efeitos secundários comuns (podem afetar mais de 1 em 10 pessoas)

• Nausea
• Diarrhoea
• Vomiting
• Constipation
• Abdominal pain or discomfort

These gastrointestinal effects are most common during the first weeks of tratamento and typically become less severe over time. Eating smaller meals, avoiding high-fat foods, and staying well-hydrated may help manage them.

Menos comuns but serious efeito secundários

• Pancreatitis: Persistent severe abdominal pain that may radiate to the back. Stop tratamento and procure assistência médica imediata if this occurs.
• Gallbladder problems: Including gallstones (cholelithiasis) and cholecystitis. Report any upper-right abdominal pain, fever, or jaundice to a médico promptly.
• Diabetic retinopathy complications: Reported in pacientes with pre-existing diabetic eye disease. Regular eye examinations are recommended.
• Hypoglycaemia: Risk is increased when semaglutide is used in combination with insulin or sulphonylureas.
• Acute kidney injury: Typically secondary to dehydration caused by gastrointestinal efeito secundários.
• Allergic reactions: Serious allergic reactions, including anaphylaxis, have been reported rarely.

This is not a complete list of efeito secundários. Refer to the EMA-approved product information for full prescribing details.

Ozempic vs alternativas

Several GLP-1 receptor agonists and weight management medicamentos are available in Europe. The table below provides a factual comparison for informational purposes only. A médico must assess which, if any, of these medicamentos is appropriate for an individual paciente.

Medicine	Active Ingredient	Form	Typical Dose	Approved Indication
Ozempic	Semaglutide	Weekly injeção	0.5–2 mg/week	Type 2 diabetes (EU)
Wegovy	Semaglutide	Weekly injeção	Up to 2.4 mg/week	Weight management (EU)
Saxenda	Liraglutide	Daily injeção	Up to 3 mg/day	Weight management (EU)

Key differences:

• Ozempic vs Wegovy: Both contain semaglutide. Ozempic carries an EMA approval for type 2 diabetes at doses up to 2 mg. Wegovy is approved specifically for chronic weight management at a higher maximum dose of 2.4 mg. Clinical evidence supports greater average weight loss at the higher Wegovy dose.
• Ozempic vs Saxenda: Saxenda contains liraglutide, a different GLP-1 agonist that requires daily (rather than weekly) injeçãos. Clinical head-to-head data indicates semaglutide (Ozempic/Wegovy) produces greater mean weight loss than liraglutide (Saxenda) over comparable tratamento periods, per published clinical trial data referenced by the EMA.

Como obter Ozempic online na Europa

Ozempic is a medicamento sujeito a receita médica (POM) in all estados-membros da UE. It cannot be legally dispensed without a valid receita médica from a licensed medical professional.

Prescrivia operates as a technology intermediary: we do not prescribe medicamentos, employ médicos, or sell medicamentos. Instead, our platform connects pacientes with independent EU-registered médicos who can conduct confidential online health assessments.

The process works as follows:

1. Complete uma avaliação de saúde: Answer a structured set of health questions designed to capture relevant medical history, current medications, and tratamento goals. This assessment is reviewed by an independent médico.
2. Avaliação médica: An independent EU-registered médico reviews your assessment. If semaglutide is clinically appropriate for you, they may issue a receita médica. If it is not appropriate, the médico will explain why.
3. Receita e dispensa: If a receita médica is issued, it is sent to a licensed EU farmácia partner. The farmácia dispenses and ships the medicamento directly to you.

Important: A Prescrivia não garante that a receita médica will be issued. All prescribing decisions are made independently by qualified medical professionals based on your individual clinical circumstances.

Informação de segurança importante

Não utilize Ozempic if you:

• Have a personal or family history of medullary thyroid carcinoma (MTC)
• Have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Are allergic to semaglutide or any other ingredient in Ozempic
• Are pregnant, planning to become pregnant, or breastfeeding

Informe o seu médico before starting Ozempic if you have:

• A history of pancreatitis
• Diabetic retinopathy
• Kidney disease
• Liver disease
• Gallbladder disease
• A history of eating disorders

Interações medicamentosas: Ozempic may interact with other medications, particularly insulin and sulphonylureas (risk of hypoglycaemia), and oral contraceptives (potential reduced absorption due to delayed gastric emptying). Always disclose all current medications to your médico during the assessment.

Ozempic is not a substitute for lifestyle changes. Dietary modification and regular physical activity remain important components of any weight management or diabetes tratamento plan.

Fontes

Medical information on this page is based on the following sources:

• Agência Europeia de Medicamentos (EMA). Ozempic (semaglutide) — Summary of Product Characteristics. Available at: ema.europa.eu
• Agência Europeia de Medicamentos (EMA). Assessment report: Ozempic. EMEA/H/C/004174.
• Organização Mundial da Saúde (WHO). Obesity and overweight — Fact sheet. who.int
• Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989-1002.

This content is reviewed periodically to reflect updated clinical guidance. It is provided for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for advice relevant to your individual health circumstances.